Showing results (121-130 of 738) with videos related to
Sort By:
Pageof 74
Clinical Chemistry|April 1, 1981
A strategy for radioimmunoassay of plasma progesterone with use of a homologous-site 125I-labeled radioligandJ E Corrie, W M Hunter, J S MacphersonCommunications Chemistry|August 8, 2024
Selection of antibody-binding covalent aptamersNoah Soxpollard, Sebastian Strauss, Ralf Jungmann, et al.Journal of the American Society for Mass Spectrometry|November 15, 2013
Characterization of a high-pressure quadrupole collision cell for low-energy collision-indneed dissociationM Morris, P Thibault, R K BoydBone|February 1, 2011
Increased bone strength is associated with improved bone microarchitecture in intact female rats treated with strontium ranelate: a finite element analysis studySteven K Boyd, Eva Szabo, Patrick AmmannMolecular Genetics and Metabolism Reports|June 9, 2020
Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to EliglustatKaramjot Sidhu, Steven K Boyd, Aneal KhanPhysiological and Biochemical Zoology : PBZ|September 8, 2009
Thermal acclimation and regulation of metabolism in a reptile (Crocodylus porosus): the importance of transcriptional mechanisms and membrane compositionF Seebacher, S A Murray, P L ElseHuman Reproduction (Oxford, England)|July 2, 2003
Human 'testicular dysgenesis syndrome': a possible model using in-utero exposure of the rat to dibutyl phthalateJane S Fisher, S Macpherson, N Marchetti, et al.Annals of the Royal College of Surgeons of England|May 23, 2023
Metastases from gastric cancer presenting as colorectal lesions: a report of two cases and systematic reviewV L Fretwell, E G Kane, S MacPherson, et al.Anti-Cancer Drug Design|October 1, 1995
Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugsI Meikle, J Cummings, J S Macpherson, et al.Journal of Chromatography. B, Biomedical Applications|October 11, 1996
Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatographyJ Cummings, I Meikle, J S Macpherson, et al.Pageof 74